ConductScience.org, home

Comparison · NCT01799993-ca2af551

Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants With Microbiological Recurrence at LFU Visit

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants With Microbiological Recurrence at LFU Visit. Trial comparisons, record NCT01799993-ca2af551. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01799993-ca2af551

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.04710.02710.0804wilson
Risk in group 20.04740.02730.0811wilson
Risk difference, group 1 minus group 2-0.000372-0.03950.0386newcombe hybrid score
Risk ratio, group 1 over group 20.9920.4542.17log
Odds ratio, group 1 over group 20.9920.4372.25log
Number needed to treat, for one fewer participant with the outcome on Amikacin Inhale (BAY41-6551) than on Placebo2,690from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Amikacin Inhale (BAY41-6551)Participants received 400 mg (3.2 mL) aerosolized Amikacin (BAY41-6551) solution every 12 hours via Pulmonary Drug Delivery System (PDDS) Clinical from Day 1 to Day 10.12255OG000
Group 2PlaceboParticipants received 3.2 mL aerosolized placebo solution every 12 hours via PDDS Clinical from Day 1 to Day 10.12253OG001

Outcome

Type
OTHER_PRE_SPECIFIED
Title
Number of Participants With Microbiological Recurrence at LFU Visit
Description
The responses of recurrence were tabulated for each participant. Recurrence was defined as the reappearance of the original pathogen(s) from a specimen taken after the TOC visit. If one or more pathogen reappeared, all isolates from a participant were tabulated as recurrence. Baseline pathogen was defined as pathogens tested at Screening and Day 1 visit by central laboratory.
Time frame
Up to 28-32 days after start of study treatment
Population
mITT population

Source ClinicalTrials.gov

Trial

Title
Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
NCT number
NCT01799993
Phases
PHASE3
Conditions
Pneumonia, Bacterial
Interventions
Amikacin Inhalation Solution (BAY41-6551), Aerosolized Placebo
Lead sponsor
Bayer
Results first posted
2018-06-26

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01799993-ca2af551